Literature DB >> 17494927

Case-control study of human papillomavirus and oropharyngeal cancer.

Gypsyamber D'Souza1, Aimee R Kreimer, Raphael Viscidi, Michael Pawlita, Carole Fakhry, Wayne M Koch, William H Westra, Maura L Gillison.   

Abstract

BACKGROUND: Substantial molecular evidence suggests a role for human papillomavirus (HPV) in the pathogenesis of oropharyngeal squamous-cell carcinoma, but epidemiologic data have been inconsistent.
METHODS: We performed a hospital-based, case-control study of 100 patients with newly diagnosed oropharyngeal cancer and 200 control patients without cancer to evaluate associations between HPV infection and oropharyngeal cancer. Multivariate logistic-regression models were used for case-control comparisons.
RESULTS: A high lifetime number of vaginal-sex partners (26 or more) was associated with oropharyngeal cancer (odds ratio, 3.1; 95% confidence interval [CI], 1.5 to 6.5), as was a high lifetime number of oral-sex partners (6 or more) (odds ratio, 3.4; 95% CI, 1.3 to 8.8). The degree of association increased with the number of vaginal-sex and oral-sex partners (P values for trend, 0.002 and 0.009, respectively). Oropharyngeal cancer was significantly associated with oral HPV type 16 (HPV-16) infection (odds ratio, 14.6; 95% CI, 6.3 to 36.6), oral infection with any of 37 types of HPV (odds ratio, 12.3; 95% CI, 5.4 to 26.4), and seropositivity for the HPV-16 L1 capsid protein (odds ratio, 32.2; 95% CI, 14.6 to 71.3). HPV-16 DNA was detected in 72% (95% CI, 62 to 81) of 100 paraffin-embedded tumor specimens, and 64% of patients with cancer were seropositive for the HPV-16 oncoprotein E6, E7, or both. HPV-16 L1 seropositivity was highly associated with oropharyngeal cancer among subjects with a history of heavy tobacco and alcohol use (odds ratio, 19.4; 95% CI, 3.3 to 113.9) and among those without such a history (odds ratio, 33.6; 95% CI, 13.3 to 84.8). The association was similarly increased among subjects with oral HPV-16 infection, regardless of their tobacco and alcohol use. By contrast, tobacco and alcohol use increased the association with oropharyngeal cancer primarily among subjects without exposure to HPV-16.
CONCLUSIONS: Oral HPV infection is strongly associated with oropharyngeal cancer among subjects with or without the established risk factors of tobacco and alcohol use. Copyright 2007 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17494927     DOI: 10.1056/NEJMoa065497

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  809 in total

1.  An oral cavity squamous cell carcinoma quantitative histomorphometric-based image classifier of nuclear morphology can risk stratify patients for disease-specific survival.

Authors:  Cheng Lu; James S Lewis; William D Dupont; W Dale Plummer; Andrew Janowczyk; Anant Madabhushi
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 2.  HPV-associated head and neck cancer: a virus-related cancer epidemic.

Authors:  Shanthi Marur; Gypsyamber D'Souza; William H Westra; Arlene A Forastiere
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

3.  Obesity and head and neck cancer risk and survival by human papillomavirus serology.

Authors:  Xinmiao Tan; Heather H Nelson; Scott M Langevin; Michael McClean; Carmen J Marsit; Tim Waterboer; Michael Pawlita; Karl T Kelsey; Dominique S Michaud
Journal:  Cancer Causes Control       Date:  2014-11-15       Impact factor: 2.506

4.  History of diabetes and risk of head and neck cancer: a pooled analysis from the international head and neck cancer epidemiology consortium.

Authors:  Marni Stott-Miller; Chu Chen; Shu-Chun Chuang; Yuan-Chin Amy Lee; Stefania Boccia; Hermann Brenner; Gabriela Cadoni; Luigino Dal Maso; Carlo La Vecchia; Philip Lazarus; Fabio Levi; Keitaro Matsuo; Hal Morgenstern; Heiko Müller; Joshua Muscat; Andrew F Olshan; Mark P Purdue; Diego Serraino; Thomas L Vaughan; Zuo-Feng Zhang; Paolo Boffetta; Mia Hashibe; Stephen M Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-12-05       Impact factor: 4.254

5.  Epidemiology of head and neck squamous cell cancer among HIV-infected patients.

Authors:  Gypsyamber Dʼsouza; Thomas E Carey; William N William; Minh Ly Nguyen; Eric C Ko; James Riddell; Sara I Pai; Vishal Gupta; Heather M Walline; J Jack Lee; Gregory T Wolf; Dong M Shin; Jennifer R Grandis; Robert L Ferris
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

6.  Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice.

Authors:  Julie Ahn; Shiwen Peng; Chien-Fu Hung; Richard B S Roden; Simon R Best
Journal:  Laryngoscope       Date:  2017-09-04       Impact factor: 3.325

7.  Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal.

Authors:  Van K Morris; Asif Rashid; Miguel Rodriguez-Bigas; Prajnan Das; George Chang; Aki Ohinata; Jane Rogers; Christopher Crane; Robert A Wolff; Cathy Eng
Journal:  Oncologist       Date:  2015-09-17

8.  Matrix-metalloproteinases in head and neck carcinoma-cancer genome atlas analysis and fluorescence imaging in mice.

Authors:  Samantha J Hauff; Sharat C Raju; Ryan K Orosco; Andrew M Gross; Julio A Diaz-Perez; Elamprakash Savariar; Nadia Nashi; Jonathan Hasselman; Michael Whitney; Jeffrey N Myers; Scott M Lippman; Roger Y Tsien; Trey Ideker; Quyen T Nguyen
Journal:  Otolaryngol Head Neck Surg       Date:  2014-08-04       Impact factor: 3.497

Review 9.  Tumor Microenvironment in Head and Neck Squamous Cell Carcinomas.

Authors:  Görkem Eskiizmir
Journal:  Turk Arch Otorhinolaryngol       Date:  2015-09-01

10.  Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners.

Authors:  Gypsyamber D'Souza; Neil D Gross; Sara I Pai; Robert Haddad; Karen S Anderson; Shirani Rajan; Jennifer Gerber; Maura L Gillison; Marshall R Posner
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.